University of Wolverhampton
Browse
Collection All
bullet
bullet
bullet
bullet
Listed communities
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet
bullet

Wolverhampton Intellectual Repository and E-Theses > Research Institutes > Research Institute in Healthcare Science > Molecular Immunology Research Group  > Molecular pathology of brain tumours - how will molecular and cell biology contribute to improved outcomes in patients with malignant brain tumours?

Please use this identifier to cite or link to this item: http://hdl.handle.net/2436/30214
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!



Title: Molecular pathology of brain tumours - how will molecular and cell biology contribute to improved outcomes in patients with malignant brain tumours?
Other Titles: In: The 33rd Congress of the Czech Society of Pathologists, 2nd Satellite Symposium & Workshop on Molecular Pathology, Regional Centre Olomouc & Faculty of Medicine, Palacky University Olomouc, May 4–6, 2006, 20-22
Authors: Darling, John L.
Citation: Biomedical Papers, 150(Suppl 1): 20-22
Publisher: Czech Republic: Palacky University, Olomouc: Faculty of Medicine and Dentistry
Journal: Biomedical Papers
Issue Date: 2006
URI: http://hdl.handle.net/2436/30214
Additional Links: http://publib.upol.cz/~obd/fulltext/Biomed/2006/Suppl.1/1.pdf
Abstract: Although in comparison to breast, lung and colon cancer, the brain is a relatively uncommon site for the development of cancer, the brain is the tenth most common site for the development of cancer in men and about the twelfth in women. This translates to about 6,000 individuals in the UK developing a primary malignant brain tumour every year. Cancer of the brain develops in two distinct age groups, although the types of tumour that develop in these two age groups differ markedly. There is a peak of incidence in the first decade of life, and brain tumours rank with leukaemia as a leading cause of cancer death in children. These tumours tend to be indolent low-grade astrocytomas or highly malignant primitive neuroectodermal tumours like medulloblastoma. However, the vast majority of brain tumours occur with increasing frequency in the sixth, seventh and eight decade of life and they are the second fastest growing cause of cancer death among those over 65. These tumours tend to be malignant astrocytomas particularly the most malignant variety, glioblastoma multiforme (GBM). Unlike lung cancer or malignant melanoma there is no strong evidence of an environmental carcinogen associated with the development of these tumours and no change in behaviour reduces risk.
Type: Meetings & Proceedings
Language: en
Description: The author is extremely grateful for the financial support by the Brain Research Trust, Samantha Dickson Research Trust, Brain Tumour UK, the Colin Oliphant Trust and the University of Wolverhampton. Abstract is provided here courtesy of Palacky University, Olomouc.
Keywords: Oncology
Brain Tumours
Malignant tumours
Astrocytoma
Glioma
Glioblastoma Multiforme
GBM
TP53
Chromosomal Aberrations
Genomics
Drug resistance
Molecular Biology
ISSN: 1213-8118
Appears in Collections: Molecular Immunology Research Group
Cancer Research Group

Files in This Item:
File Description Size Format View/Open
Darling 20-22 2006.pdfDarling (2006) Biomedical Papers 150661KbAdobe PDFThumbnail
View/Open

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Fairtrade - Guarantees a better deal for Third World Producers

University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1LY

Course enquiries: 0800 953 3222, General enquiries: 01902 321000,
Email: enquiries@wlv.ac.uk | Freedom of Information | Disclaimer and copyright | Website feedback | The University as a charity

OR Logo Powered by Open Repository | Cookies